Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jun;49(6):470–473. doi: 10.1136/jcp.49.6.470

Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.

Y Soini 1, N Virkajärvi 1, H Raunio 1, P Pääkkö 1
PMCID: PMC500536  PMID: 8763260

Abstract

AIMS: (1) To investigate the immunohistochemical expression of the multidrug resistance gene (MDR1) product P-glycoprotein in histological samples from 31 hepatocellular carcinomas (HCCs); and (2) to correlate the results with cell proliferation, p53 expression, the disease-free interval, and cumulative patient survival. METHODS: C219 (a monoclonal antibody), CM-1 (a polyclonal rabbit anti-human antibody) and PC10 (a monoclonal mouse anti-human antibody) were used to detect expression of P-glycoprotein, p53 and proliferating cell nuclear antigen (PCNA), respectively, by means of the avidin-biotin peroxidase method. RESULTS: Membrane bound positivity for P-glycoprotein was observed in 20 (65%) of the 31 HCCs. Cytoplasmic globular positivity was also seen in some cases. There were no significant associations between expression of P-glycoprotein and cell proliferation (determined by PCNA immunoexpression and the mitotic count), or p53 expression. Patients with P-glycoprotein positive tumours had a shorter disease-free interval than those with P-glycoprotein negative tumours, and also had a shorter survival time. There was no difference in survival between P-glycoprotein positive patients who had or had not received chemotherapy, suggesting that chemotherapy (mainly mitomycin-C) did not affect survival in these patients. CONCLUSIONS: Expression of P-glycoprotein in HCCs is associated with a shorter disease-free interval and shorter survival time. As expression of P-glycoprotein was not associated with cell proliferation or expression of p53, its effect on disease progression and survival seems to be independent of these factors.

Full text

PDF
470

Images in this article

471Image
on p.471
472Image
on p.472

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Charpin C., Vielh P., Duffaud F., Devictor B., Andrac L., Lavaut M. N., Allasia C., Horschowski N., Piana L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst. 1994 Oct 19;86(20):1539–1545. doi: 10.1093/jnci/86.20.1539. [DOI] [PubMed] [Google Scholar]
  2. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992 Jan 24;255(5043):459–462. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  3. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277–1287. doi: 10.1177/38.9.1974900. [DOI] [PubMed] [Google Scholar]
  4. De Angelis P., Stokke T., Smedshammer L., Lothe R. A., Lehne G., Chen Y., Clausen O. P. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer. 1995 Aug;72(2):307–311. doi: 10.1038/bjc.1995.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dietel M. What's new in cytostatic drug resistance and pathology. Pathol Res Pract. 1991 Sep;187(7):892–905. doi: 10.1016/S0344-0338(11)80589-3. [DOI] [PubMed] [Google Scholar]
  6. Duensing S., Dallmann I., Grosse J., Buer J., Lopez Hänninen E., Deckert M., Störkel S., Kirchner H., Poliwoda H., Atzpodien J. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology. 1994 Jul-Aug;51(4):309–313. doi: 10.1159/000227355. [DOI] [PubMed] [Google Scholar]
  7. EDMONDSON H. A., STEINER P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954 May;7(3):462–503. doi: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  8. Gottesman M. M. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993 Feb 15;53(4):747–754. [PubMed] [Google Scholar]
  9. Itsubo M., Ishikawa T., Toda G., Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer. 1994 Jan 15;73(2):298–303. doi: 10.1002/1097-0142(19940115)73:2<298::aid-cncr2820730211>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  10. Kramer R., Weber T. K., Morse B., Arceci R., Staniunas R., Steele G., Jr, Summerhayes I. C. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer. 1993 May;67(5):959–968. doi: 10.1038/bjc.1993.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Park J. G., Lee S. K., Hong I. G., Kim H. S., Lim K. H., Choe K. J., Kim W. H., Kim Y. I., Tsuruo T., Gottesman M. M. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst. 1994 May 4;86(9):700–705. doi: 10.1093/jnci/86.9.700. [DOI] [PubMed] [Google Scholar]
  12. Silverman J. A., Thorgeirsson S. S. Regulation and function of the multidrug resistance genes in liver. Prog Liver Dis. 1995;13:101–123. [PubMed] [Google Scholar]
  13. Sinicrope F. A., Hart J., Brasitus T. A., Michelassi F., Lee J. J., Safa A. R. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994 Dec 1;74(11):2908–2917. doi: 10.1002/1097-0142(19941201)74:11<2908::aid-cncr2820741104>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  14. Soini Y., Päkkö P., Nuorva K., Kamel D., Lane D. P., Vähäkangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A Pathol Anat Histopathol. 1992;421(3):223–228. doi: 10.1007/BF01611179. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES